All In Biotech

Drug Trial Radar · NCT07038343

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

A Phase 1/2, First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors

Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

480

Planned (sponsor's estimate)

Start

Jun 4, 2025

Primary completion

Jun 2030

Study completion Dec 2030

Sponsor

Lead sponsor
Avenzo Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
DualityBio Inc.
First posted
Jun 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy and potentially in combination therapy to patients with locally advanced or metastatic epithelial solid tumors.

Conditions

  • Solid Tumor Cancer
  • Locally Advanced
  • Metastatic Solid Tumors
  • Lung Cancers
  • Epithelial Tumor
  • Biliary Tract Cancer (BTC)
  • Urothelial Cancer
  • Nasopharyngeal Cancers

Interventions

  • AVZO-1418Drug

    Specific dose in protocol specified schedule

  • Combination Agent 1Drug

    Per label based on combination agent used

  • Combination Agent 2Drug

    Per label based on combination agent used

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of Dose Limiting Toxicities (DLTs) during the first cycle (Phase 1)Time frame: Approximately 2 years
  2. Determine the maximum tolerated dose (MTD) and/or preliminary recommended Phase 2 dose (RP2D) (Phase 1)Time frame: Approximately 16 months
  3. Number of Participants with Treatment Emergent Adverse Events (TEAEs) and lab abnormalities (Phase 1)Time frame: From baseline until end of study treatment or study completion (approximately 2 years)
  4. Objective Response Rate (ORR) (Phase 2)Time frame: From baseline through disease progression or study completion (approximately 2 years)

Locations

27 sites in 2 countries. Site status is shown where the registry gives one.

  • Avenzo Therapeutics Recruiting Site

    Gilbert, Arizona · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Los Angeles, California · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Los Angeles, California · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Denver, Colorado · Recruiting

  • Avenzo Therapeutics Recruiting Site

    New Haven, Connecticut · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Washington D.C., District of Columbia · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Orlando, Florida · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Sarasota, Florida · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Tampa, Florida · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Atlanta, Georgia · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Boston, Massachusetts · Recruiting

  • Avenzo Therapeutics Recruiting Site

    New York, New York · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Philadelphia, Pennsylvania · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Dallas, Texas · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Houston, Texas · Recruiting

  • Avenzo Therapeutics Recruiting Site

    San Antonio, Texas · Recruiting

  • Avenzo Therapeutics Recruiting Site

    West Valley City, Utah · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Fairfax, Virginia · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Seattle, Washington · Recruiting

  • DualityBio Recruiting Site

    Beijing, Beijing Municipality, China · Recruiting

  • DualityBio Recruiting Site

    Chongqing, Chongqing Municipality, China · Recruiting

  • DualityBio Recruiting Site

    Harbin, Heilongjiang, China · Recruiting

  • DualityBio Recruiting Site

    Zhengzhou, Henan, China · Recruiting

  • DualityBio Recruiting Site

    Changsha, Hunan, China · Recruiting

  • DualityBio Recruiting Site

    Nanchang, Jiangxi, China · Recruiting

  • DualityBio Recruiting Site

    Shenyang, Liaoning, China · Recruiting

  • DualityBio Recruiting Site

    Jinan, Shandong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.